Search company, investor...


Founded Year


About Amica

Amica operates as a manufacturer and supplier of household appliances. The company offers products such as standing kitchens, ovens, plates, hoods, heating drawers, refrigerators, wine coolers, dishwashers, microwave ovens, and more. It was founded in 1945 and is based in Wronki, Poland.

Headquarters Location

Mickiewicza, 52

Wronki, 64-510,


Missing: Amica's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Amica's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Amica News

Immunai and Baylor College of Medicine Provide Updated Interim Phase 1 Results for anti-GD2 CAR NKT-Cell Therapy in Relapsed/Refractory Neuroblastoma

May 15, 2023

4 minute read NEW YORK–(BUSINESS WIRE)–Investigators from Baylor College of Medicine (BCM) in collaboration with Immunai have published results from a clinical study in which Immunai’s technology helped identify BTG1 as a novel molecular target that can be used to enhance the potency of natural killer T (NKT)- and T cell-based cancer immunotherapy. The study was published today in Nature Medicine . As part of this collaboration, Immunai leveraged its advanced multi-omics platform to analyze clinical samples from an ongoing trial conducted at BCM. These studies led to the identification of BTG1 as a novel driver of NKT cell hyporesponsiveness that can be targeted to enhance CAR-NKT cell anti-tumor function. This discovery has the potential to improve the ability of NKT and T cell therapy products to target and eliminate malignant cells. BCM conducted extensive in vitro and in vivo studies to validate the superior anti-tumor activity of CAR-NKT cells modified to target BTG1, demonstrating the potential of this approach for use as a cutting-edge therapy. Importantly, CAR-NKT cells genetically modified to target BTG1 were able to overcome exhaustion, a major obstacle for developing effective cell therapy products. This breakthrough is significant as it opens the door to more effective and targeted immunotherapies to treat a range of malignancies and other diseases. By combining Immunai’s expertise in multi-omics platforms with BCM’s research capabilities, the collaboration has paved the way for innovative treatment options that could improve patient outcomes worldwide. “This project highlights Immunai’s platform capabilities in discovering and improving therapeutics, applicable to diverse types of cell therapies and other immune modulating therapies within oncology and inflammatory diseases,” said Noam Solomon, CEO of Immunai. “Immunai has been committed from the beginning to developing its cutting-edge platform to deliver actionable therapeutic insights that have the potential to transform patients’ lives, and our work with BCM is also a great reflection of our commitment to improving clinical outcomes with our partners.” “Effectively harnessing knowledge from precious patient samples poses a paramount challenge in clinical research. The state-of-the-art single-cell RNA sequencing technology developed by Immunai allowed us to accurately measure gene expression changes in thousands of individual CAR-NKT cells before and after infusion into patients. The discoveries made during BCM and Immunai’s productive collaboration have already resulted in two Nature Medicine publications in less than three years and informed the development of more effective cancer immunotherapy,” said Dr. Leonid Metelitsa, Director, Center for Advanced Innate Cell Therapy at Texas Children’s Hospital and Baylor College of Medicine. The study was made possible through a long-standing collaboration between the two organizations structured around joint IP ownership, highlighting the power of combining industry-leading technology with top-tier academic research. About Immunai Founded in 2018, Immunai (New York HQ, offices in Tel-Aviv, Zurich and Prague) is an immune-profiling platform company for improving therapeutic discovery and development by measuring immunomics with single-cell resolution. Immunai holds the largest proprietary clinico-omics database AMICA™ for the human immune system from 10,000s of patients and spanning over 500 indications. Its core immune profiling platform leverages multi-modal profiling of immune cells of patients with single-cell resolution. The data is uploaded and harmonized in AMICA with engineering and ML infrastructure, and then mined for immune-driven therapeutic insights.Immunai is partnering with top hospitals, biopharma and biotechnology companies to co-develop novel therapeutics as well as accelerate clinical development programs with Immunai’s platform. About Baylor College of Medicine Baylor College of Medicine ( ) in Houston is recognized as a health sciences university and is known for excellence in education, research and patient care. It is ranked 22nd among medical schools for research and 31st for primary care by U.S. News & World Report. Baylor is listed 20th among all U.S. medical schools for National Institutes of Health funding and No. 1 in Texas. Located in the Texas Medical Center, Baylor has affiliations with seven teaching hospitals and jointly owns and operates Baylor St. Luke’s Medical Center, part of St. Luke’s Health. Currently, Baylor has more than 3,000 trainees in medical, graduate, nurse anesthesia, physician assistant, orthotics and genetic counseling as well as residents and postdoctoral fellows. Contacts

Amica Frequently Asked Questions (FAQ)

  • When was Amica founded?

    Amica was founded in 1945.

  • Where is Amica's headquarters?

    Amica's headquarters is located at Mickiewicza, 52, Wronki.

  • Who are Amica's competitors?

    Competitors of Amica include Dawlance and 4 more.

Compare Amica to Competitors

Percon Polska

Percon Polska is an enterprise that operates in the household appliances and electrical and electronic goods wholesaler industry. It offers a full range of Percon cables, Gefen signal distribution and extension devices, AVP matrix switchers' connection panels, Televic Conference discussion systems, and more. It was founded in 2007 and is based in Warszawa, Poland.


ASKOM is an integrator of automation systems and production management systems (MES) and a producer of industrial software. It offers solutions in integrated automation technology, which consists of SIMATIC, WinCC, PCS7, SIMATIC BATCH, and SIMATIC IT systems (MES compliant with the ISA95 standard). It also offers GE FANUC and Beckhoff controllers, the Metso DNA system, and InTouch and iFIX visualization systems. It serves the food industry, the power, chemistry, coke, and machinery industries. It was founded in 1993 and is based in Gliwice, Poland.


Solwena develops an energy management system. The company offers to optimize the management of devices in facilities, record energy consumption, integrate automation systems with external information systems, and more. It was founded in 2016 and is based in Gdansk, Poland.


AB-Micro specializes in providing comprehensive industrial automation solutions. It was founded in 1984 and is based in Warsaw, Poland.

Grupa GP

Grupa GP is a business-to-business (B2B) platform and manages brands. Its brands include Techlife, Vsett, Airwheel, and Holding Hands. It offers products such as electric vehicles, accessories, medical vehicles, and more. It was founded in 2016 and is based in Zabrze, Poland.


Advatech is an IT company. It supplies mass storage, virtualization solutions, and security solutions. It offers infrastructure, data protection, high-availability systems, VDI, security, automation, ITSM systems, and other services. It was founded in 1998 and is based in Wroclaw, Poland.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.